M. O’connell

发表

J. Bruzzi, M. O’connell, J. Murray, 2001, The New England journal of medicine.

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

B. Freidlin, D. Gandara, F. Shepherd, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial.

J. O'fallon, M. O’connell, E. Creagan, 1979, The New England journal of medicine.

Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

N. Petrelli, N. Wolmark, M. O’connell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer

J. O'fallon, M. O’connell, V. Go, 1986, Cancer.

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

N. Petrelli, N. Wolmark, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.

C. Begg, J. Glick, M. O’connell, 1980, Cancer treatment reports.

Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study.

M. Oken, M. O’connell, N. Kay, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative screening of patients with carcinoma of the colon

R. Beart, M. O’connell, A. Schutt, 1981, Diseases of the colon and rectum.

Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

N. Petrelli, N. Wolmark, M. O’connell, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative adjuvant therapy of rectal cancer: an analysis of disease control, survival, and prognostic factors.

M. O’connell, S. Schild, D. Ilstrup, 1989, International journal of radiation oncology, biology, physics.

Adjuvant therapy for adenocarcinoma of the rectum

M. O’connell, L. Gunderson, 1992, World Journal of Surgery.

Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer

A. Weaver, M. O’connell, D. Ilstrup, 1995, Cancer.

Current issues in the treatment of colorectal cancer.

R. Beart, M. O’connell, L. Gunderson, 1986, Critical reviews in oncology/hematology.

Residual, recurrent, or unresectable gastrointestinal cancer. Role of radiation in single or combined modality treatment

J. K. Martin, R. Beart, D. Nagorney, 1985, Cancer.

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

N. Petrelli, N. Wolmark, M. O’connell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

N. Wolmark, M. O’connell, C. Allegra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computed tomography in search of cancer of unknown origin.

P. Sheedy, M. O’connell, P. Karsell, 1982, JAMA.

Reply to R. Glynne-Jones et al

N. Wolmark, M. O’connell, M. Deutsch, 2010 .

Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value

N. Petrelli, S. Paik, Chungyeul Kim, 2012 .

A comparative clinical and immunological assessment of methanol extraction residue of Bacillus Calmette-Guérin versus placebo in patients with advanced cancer.

M. O’connell, S. Frytak, C. Moertel, 1979, Cancer research.

Recombinant interferon‐γ lacks activity against metastatic colorectal cancer but increases serum levels of ca 19‐9

M. O’connell, C. Moertel, A. Schutt, 1989, Cancer.

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer.

R. Fitzgibbons, J. Donohue, J. Krook, 1995, Journal of Clinical Oncology.

Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?

D. Schaid, S. Thibodeau, J. Kovach, 1992, Cancer.

Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas.

F. Sim, T. Fleming, M. O’connell, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

J. Kopec, D. Cella, J. Costantino, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial of 5‐fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study

M. O’connell, 1989, Cancer.

Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)

V. Devita, M. O’connell, P. Schein, 1974, Cancer.

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

M. O’connell, D. Haller, G. Yothers, 2014, The Lancet. Oncology.

Curative Potential of Multimodality Therapy for Locally Recurrent Rectal Cancer

S. Cha, D. Sargent, H. Nelson, 2003, Annals of surgery.

REPEATED ADJUVANT CHEMOTHERAPY WITH PHENYLALANINE MUSTARD OR 5-FLUOROURACIL, CYCLOPHOSPHAMIDE, AND PREDNISONE WITH OR WITHOUT RADIATION, AFTER MASTECTOMY FOR BREAST CANCER

J. O'fallon, W. Payne, J. Ingle, 1978, The Lancet.

Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.

C. V. Linden, M. O’connell, T. J. Vecchio, 1982, Archives of internal medicine.

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.

L. Kvols, M. O’connell, R. Hahn, 1986, The New England journal of medicine.

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

N. Petrelli, R. Beart, N. Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database.

J. Meyerhardt, E. Van Cutsem, M. O’connell, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10.

N. Petrelli, N. Wolmark, M. O’connell, 2010 .

Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.

M. O’connell, D. Haller, G. Yothers, 2012 .

The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer.

N. Petrelli, N. Wolmark, M. O’connell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential regional differences for the tolerability profiles of fluoropyrimidines.

E. Van Cutsem, J. Tabernero, J. Bertino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

N. Wolmark, M. O’connell, G. Yothers, 2008, Cancer investigation.

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.

H. Wieand, J. Krook, M. O’connell, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

M. O’connell, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin

N. Wolmark, M. O’connell, Roy E. Smith, 2007, Cancer.

Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.

D. Nagorney, T. Smyrk, M. O’connell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.

R. Goldberg, M. O’connell, C. Erlichman, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03

N. Petrelli, N. Wolmark, M. O’connell, 2005 .

Current status of adjuvant therapy for colorectal cancer.

M. O’connell, 2004, Oncology.

Intraoperative electron radiotherapy as a component of salvage therapy for patients with colorectal cancer and advanced nodal metastases.

J. Donohue, H. Nelson, D. Nagorney, 2003, International journal of radiation oncology, biology, physics.

Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program.

D. Sargent, R. Goldberg, J. Krook, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of postoperative follow-up tests in colon cancer patients treated for cure.

J. O'fallon, P. Novotny, C. Loprinzi, 1997, Oncology.

Antipyrimidines: 5-Fluorouracil and 5-Fluoro-2′-Deoxyuridine

M. O’connell, 1987 .

Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.

M. O’connell, J. Rubin, D. Ilstrup, 1985, Mayo Clinic proceedings.

Combined-modality neoadjuvant therapy for rectal cancer.

M. O’connell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new predictive molecular marker for cetuximab benefit in rectal cancer?

M. O’connell, T. George, 2014, Journal of the National Cancer Institute.

North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.

M. O’connell, 2001, Seminars in oncology.

Optimum doses of irinotecan

M. O’connell, H. Pitot, C. Erlichman, 1999, The Lancet.

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.

R. Goldberg, M. O’connell, H. Pitot, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.

R. Fitzgibbons, D. Nagorney, J. Krook, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

N. Petrelli, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of intra-operative irradiation in locally advanced primary and recurrent rectal adenocarcinoma

M. O’connell, L. Gunderson, R. Dozois, 1992, World Journal of Surgery.

Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.

S. Cha, D. Sargent, J. Sloan, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New adjuvant therapy for colon cancer: justified hope or commercial hype.

M. O’connell, E. Galanis, S. Alberts, 2000, Surgical oncology clinics of North America.

Phase I study of 5‐fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy

M. O’connell, K. Rowland, P. Burch, 1999, Cancer.

Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU.

S. Cha, H. Nelson, M. O’connell, 1997, International journal of radiation oncology, biology, physics.

Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer

S. Cha, H. Nelson, M. O’connell, 1996, Diseases of the colon and rectum.

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07

N. Wolmark, M. O’connell, S. Wieand, 2005 .

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.

J. Buckner, D. Sargent, R. Goldberg, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incremental costs of enrolling cancer patients in clinical trials: a population-based study.

S. Cha, C. Chute, J. Killian, 1999, Journal of the National Cancer Institute.

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.

H. Wieand, J. Krook, M. O’connell, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.

M. O’connell, A. Soran, L. Nesbitt, 2006, Clinical colorectal cancer.

Infections in 92 splenectomized patients with Hodgkin's disease. A clinical review.

M. O’connell, P. Wiernik, S. Schimpff, 1975, The American journal of medicine.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

J. Buckner, D. Sargent, S. Hillman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Accuracy of fecal occult blood screening for colorectal neoplasia: A prospective study using Hemoccult and Hemo‐Quant tests

D. Ahlquist, M. O’connell, H. Wieand, 1993 .

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Margarita Lopatin, Greg Yothers, Carl Millward, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.

D. Kerr, N. Wolmark, R. Gray, 2010 .

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.

J. O'fallon, M. O’connell, E. Creagan, 1979, Annals of internal medicine.

Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.

J. K. Martin, R. Fitzgibbons, H. Wieand, 1990, Archives of surgery.

Local control and survival in locally advanced gastrointestinal cancer.

J. K. Martin, R. Beart, D. Nagorney, 1986, International journal of radiation oncology, biology, physics.

Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer

J. Kovach, M. O’connell, J. Reid, 1998, Cancer Chemotherapy and Pharmacology.

Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors

D. Sargent, N. Foster, M. O’connell, 2010, Clinical Cancer Research.

Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.

D. Nagorney, M. O’connell, S. Alberts, 2012, Clinical colorectal cancer.

Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non‐hodgkin's lymphoma

J. Earle, J. Glick, M. O’connell, 1988, Cancer.

The effect of intensive intermittent maintenance therapy in advanced low‐grade non‐Hodgkin's lymphoma

M. O’connell, O. Kucuk, D. Harrington, 1987, Cancer.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

D. Sargent, N. Wolmark, R. Goldberg, 2011, Journal of the National Cancer Institute.

Long-Term Foliow-Up of a CHOP-Based Regimen with Maintenance Therapy and Central Nervous System Prophylaxis in Lymphoblastic Non-Hodgkin's Lymphoma

J. Earle, T. Habermann, M. O’connell, 1994 .

DNA mismatch repair status and site of tumor recurrence in stage II and III colon cancers treated in 5-fluorouracil-based adjuvant therapy trials.

R. Labianca, D. Sargent, N. Foster, 2010 .

Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC)

D. Sargent, N. Wolmark, R. Goldberg, 2007 .

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

M. Oken, M. O’connell, H. Hochster, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CENTRAL NERVOUS SYSTEM RELAPSE IN UNFAVOURABLE-HISTOLOGY NON-HODGKIN'S LYMPHOMA: IS PROPHYLAXIS INDICATED?

M. Oken, J. Glick, M. O’connell, 1984, The Lancet.

Carcinoma of the anal canal, a clinical and pathologic study of 188 cases

R. Beart, M. O’connell, B. Boman, 1984, Cancer.

M. O’connell, R. Byhardt, J. Ruckdeschel, 1975, Medicine.

False positive lymphography in Hodgkin's disease: a histologic-lymphadenographic correlation.

M. O’connell, P. Wiernik, A. Abt, 1977, Medical and pediatric oncology.

A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5‐fluorouracil‐induced stomatitis

T. Therneau, C. Loprinzi, M. O’connell, 1990, Cancer.

Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.

S. Cha, D. Sargent, M. O’connell, 2002, International journal of radiation oncology, biology, physics.

Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).

L. Kvols, M. O’connell, R. Hahn, 1987, Annals of internal medicine.

Analgesic Efficacy of Ibuprofen for Treatment of Primary Dysmenorrhea

C. V. Linden, M. O’connell, J. Morrison, 1980, Southern medical journal.

Randomized study of combination chemotherapy in unresectable gastric cancer

M. O’connell, 1984, Cancer.

Surgical adjuvant therapy of rectal cancer.

T. Fleming, M. O’connell, L. Gunderson, 1988, Seminars in oncology.

Role of 67gallium citrate scanning in the management of non‐hodgkin's lymphoma

M. O’connell, P. Wiernik, J. Levi, 1975, Cancer.

Hepatic pathology associated with Hodgkin's disease

M. O’connell, R. Kirschner, P. Wiernik, 1974, Cancer.

Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).

S. Paik, S. Shak, N. Wolmark, 2012 .

NSABP FC‐6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild‐type liver metastases receiving mFOLFOX7 plus cetuximab

Y. Wang, N. Petrelli, K. Pogue-Geile, 2022, Journal of surgical oncology.

Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of the National Cancer Institute.

A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma

M. O’connell, 1982, Cancer.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Daniel J Sargent, Greg Yothers, Qian Shi, 2013, Clinical colorectal cancer.

Comparative evaluation of capecitabine or infusional leucovorin/5-fluorouracil (LV/5-FU) with or without oxaliplatin (Ox) for stage III colon cancer (CC): A pooled analysis of individual patient data from four randomized controlled trials.

M. O’connell, D. Haller, G. Yothers, 2012 .

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer

N. Wolmark, M. O’connell, C. Allegra, 2008 .

Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum.

N. Petrelli, N. Wolmark, M. O’connell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan for colorectal cancer: a small step forward

M. O’connell, 1998, The Lancet.

A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.

M. O’connell, J. Rubin, H. Wieand, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.

D. Sargent, R. Goldberg, J. Krook, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapid reporting and review of an increased incidence of a known adverse event.

D. Sargent, R. Goldberg, J. Krook, 2000, Journal of the National Cancer Institute.

Current status of chemotherapy for advanced pancreatic and gastric cancer.

M. O’connell, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of microsatellite instability-high remains controversial.

S. Paik, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.

N. Wolmark, M. O’connell, C. Allegra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome.

M. O’connell, J. Rubin, C. Moertel, 1986, Cancer treatment reports.

Pentostatin induces durable remissions in hairy cell leukemia.

M. O’connell, J. Bennett, D. Harrington, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience

M. O’connell, J. Bennett, M. Tallman, 2018, American journal of hematology.

Is portal-vein fluorouracil hepatic infusion effective colon cancer surgical adjuvant therapy?

M. O’connell, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A clinical trial of biochemical modulation of 5‐fluorouracil with N‐phosphonoacetyl‐L‐aspartate and thymidine in advanced gastric and anaplastic colorectal cancer

R. Goldberg, J. Laurie, J. Krook, 1990, Cancer.

Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.

J. Kovach, M. O’connell, M. Ames, 1990, Cancer research.

The significance of bone marrow involvement in non-Hodgkin's lymphoma: the Eastern Cooperative Oncology Group experience.

K. Cain, J. Glick, M. O’connell, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant lymphoma of bone

M. Ostrowski, W. Taylor, M. O’connell, 1986, Cancer.

Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer.

J. Ingle, L. Kvols, M. O’connell, 1984, Cancer treatment reports.

Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group.

L. Gordon, M. Oken, M. O’connell, 1999, Leukemia & lymphoma.

Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma: an Eastern Cooperative Oncology Group Study (PA482).

M. O’connell, P. Wiernik, M. Oken, 1998, Leukemia & lymphoma.

A comparison of cyclophosphamide, vincristine, and prednisone (COP) with nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) in the treatment of nodular, poorly differentiated, lymphocytic lymphoma

M. O’connell, R. Benjamin, P. Wiernik, 1976, Cancer.

Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early-phase trials.

N. Petrelli, R. Beart, N. Wolmark, 2014 .

A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma

M. O’connell, R. Hahn, J. Rubin, 1977, Cancer.

Allopurinol mouthwash kinetic and stability information based on normal volunteers

C. Loprinzi, M. O’connell, P. Svingen, 1989 .

A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group.

M. O’connell, 1988, Advances in experimental medicine and biology.

Brain metastases from colorectal carcinoma: The long term survivors

T. Cascino, J. Buckner, M. O’connell, 1996, Cancer.

Phase I–II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma

J. Kovach, L. Kvols, M. O’connell, 1991, Investigational New Drugs.

Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer.

J. K. Martin, J. Earle, A. Martinez, 1987, International journal of radiation oncology, biology, physics.

Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests.

H. Wieand, D. Ahlquist, C. Loprinzi, 1993, JAMA.

Prognostic significance of mediastinal mass in adult Hodgkin's disease

J. Earle, M. O’connell, P. Banks, 1984, Cancer.

Intraoperative and External Beam Irradiation for Locally Advanced Colorectal Cancer

J. K. Martin, A. Martinez, H. Wieand, 1988, Annals of surgery.

Primary lymphoma of the testis.

J. Earle, M. O’connell, P. Banks, 1982, International journal of radiation oncology, biology, physics.

Vascular invasion and hematogenous dissemination of Hodgkin's disease

M. O’connell, R. Kirschner, P. Wiernik, 1974, Cancer.

A phase I study of chlorozotocin (NSC 178248)

J. Ingle, J. Kovach, M. O’connell, 1979 .

Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Harrington, 1990, Haematology and blood transfusion.

Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group

J. Barkin, E. Livstone, P. Lavin, 1981, Cancer.

Staging laparotomy in Hodgkin's disease: Further evidence in support of its clinical utility

M. O’connell, H. Ramsey, R. Kirschner, 1974 .

Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial.

L. Collette, N. Wolmark, J. Bosset, 2016 .

Value of preoperative radionuclide bone scan in suspected primary breast carcinoma.

H. Wahner, M. O’connell, D. Ahmann, 1978, Mayo Clinic proceedings.

Escalating the intensity of postremission therapy improves the outcome in acute myeloid leukemia: The ECOG experience

M. O’connell, J. Bennett, D. Harrington, 1992 .

Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Harrington, 1992, Leukemia.

Combined doxorubicin and alpha‐interferon therapy of advanced hepatocellular carcinoma

H. Wieand, J. Krook, M. O’connell, 1993, Cancer.

Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.

M. O’connell, C. Schiffer, J. Aisner, 1976, Cancer treatment reports.

Contents Vol. 11, 2011

E. Achten, J. Neoptolemos, D. Yadav, 2012, Pancreatology.

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

J. Laurie, M. O’connell, H. Wieand, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin).

M. O’connell, J. Bennett, D. Harrington, 1987, The New England journal of medicine.

High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison.

T. Fleming, M. O’connell, M. Ames, 1985, The New England journal of medicine.

Phase II study of pyrazofurin in advanced colorectal carcinoma.

M. O’connell, E. Creagan, R. Hahn, 1977, Cancer treatment reports.

Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca

M. O’connell, R. Laibovitz, M. Silverman, 1993, Cornea.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

J. Winter, M. O’connell, J. Bennett, 1992, Annals of Hematology.

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study

J. Winter, M. O’connell, J. Bennett, 2005, Annals of Hematology.

Phase II study of cytosine arabinoside in advanced large bowel cancer.

M. O’connell, R. Hahn, J. Rubin, 1977, Cancer treatment reports.

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

L. Kvols, M. O’connell, J. Rubin, 1991, Cancer.

Varying intensity of postremission therapy in acute myeloid leukemia.

M. Oken, M. O’connell, J. Bennett, 1992, Blood.

Pilot study of PALA and 5-FU in patients with advanced cancer.

M. O’connell, G. Powis, J. Rubin, 1982, Cancer treatment reports.

Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.

L. Kvols, M. O’connell, R. Hahn, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer.

L. Kvols, M. O’connell, R. Hahn, 1987, Cancer treatment reports.

Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials.

L. Kvols, M. O’connell, G. Powis, 1986, Cancer treatment reports.

Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.

A. Tsiatis, J. Glick, M. O’connell, 1984, Cancer treatment reports.

Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).

J. Kovach, M. O’connell, C. Moertel, 1979, Cancer treatment reports.

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

D. Sargent, T. Smyrk, N. Foster, 2009, British Journal of Cancer.

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Daniel J Sargent, Daniel G Haller, Joel E Tepper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

D. Sargent, R. Goldberg, L. Burgart, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.

D. Schaid, D. Sargent, S. Thibodeau, 1999, Journal of the National Cancer Institute.

Allelic Imbalance and Microsatellite Instability in Resected Duke's D Colorectal Cancer

D. Schaid, S. Thibodeau, S. McDonnell, 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma.

M. O’connell, R. Neiman, R. Mann, 1995, Leukemia & lymphoma.

LYMPHOMA THE MANAGEMENT OF NON-HODGKIN'S

M. O’connell, P. Wiernik, J. Levi, 1975 .

Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.

D. Sargent, J. Ajani, J. Tepper, 2002, International journal of radiation oncology, biology, physics.

Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.

J. Tepper, A. Benson, M. O’connell, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

H. Wieand, J. Krook, M. O’connell, 1994, The New England journal of medicine.

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.

J. Meyerhardt, A. Benson, C. Willett, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114.

J. Tepper, M. O’connell, D. Hollis, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?

D. Schaid, S. Thibodeau, J. Cunningham, 1992 .

Impact of number of nodes retrieved on outcome in patients with rectal cancer.

C. Compton, J. Tepper, A. Benson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.

J. Tepper, A. Benson, M. O’connell, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report.

D J Sargent, D. Sargent, H. Nelson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective, randomized evaluation of intensive‐course 5‐fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer

H. Wieand, R. Beart, J. Krook, 1991, Cancer.

A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer.

L. Kvols, M. O’connell, C. Moertel, 1985, International journal of radiation oncology, biology, physics.

A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma.

M. O’connell, J. Rubin, C. Moertel, 1982, International journal of radiation oncology, biology, physics.

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia.

M. Oken, M. O’connell, J. Bennett, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.

M. O’connell, J. Bennett, D. Adelstein, 1985, Seminars in oncology.

Partial splenectomy for staging Hodgkin's disease: risk of false-negative results.

M. O’connell, J. Dearth, G. Gilchrist, 1978, The New England journal of medicine.

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

Nan Song, Greg Yothers, Norman Wolmark, 2016, JAMA oncology.

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

N. Petrelli, N. Wolmark, M. O’connell, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Greg Yothers, Hyun Joo Choi, Debora Fumagalli, 2012, Clinical Cancer Research.

Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

J. Meyerhardt, D. Sargent, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

N. Petrelli, S. Paik, N. Wolmark, 2013, Journal of the National Cancer Institute.

Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer.

D. Sargent, J. Krook, J. Kugler, 2006, Clinical colorectal cancer.

The marriage of growth factor inhibitors and chemotherapy: bliss or bust?

M. O’connell, C. Allegra, S. Staal, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas

D. Sargent, N. Foster, M. O’connell, 2008, Clinical Cancer Research.

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

D. Sargent, R. Schilsky, M. O’connell, 2001, The New England journal of medicine.

Locally advanced primary colorectal cancer: IOERT and EBRT +/-5-FU.

S. Cha, H. Nelson, M. O’connell, 1997, Frontiers of radiation therapy and oncology.

The mayo clinic experience with multimodality treatment of locally advanced or recurrent colon cancer

J. Donohue, H. Nelson, D. Nagorney, 2002, Annals of Surgical Oncology.

Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.

D. Sargent, R. Goldberg, M. O’connell, 2009, Clinical colorectal cancer.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Problems in the staging of Hodgkin disease.

M. O’connell, R. Kirschner, P. Wiernik, 1973, JAMA.

Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign?

M. O’connell, R. Kirschner, P. Wiernik, 1975, JAMA.

Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

N. Wolmark, M. O’connell, J. Dignam, 2006, Journal of the National Cancer Institute.

Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

J. Kovach, M. O’connell, J. Rubin, 1983, Cancer treatment reports.

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy

A. Degramont, R. Labianca, D. Sargent, 2013, Cancer.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

R. Beart, N. Wolmark, D. Moore, 2015, Journal of the National Cancer Institute.

Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma

R. Motzer, M. Mazumdar, K. Sell, 1995, Cancer.

Advanced diffuse non‐Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study

L. Gordon, J. Glick, M. O’connell, 1995, Cancer.

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.

S. Weitzman, M. Oken, M. O’connell, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.

J. Earle, J. Glick, M. O’connell, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1.

D. Schaid, S. Thibodeau, S. McDonnell, 1998, Cancer research.

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

D. Sargent, R. Goldberg, A. Grothey, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

J. Meyerhardt, A. Benson, C. Willett, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.

Jeffery T. Sloan, D. Sargent, N. Petrelli, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wound recurrence following conventional treatment of colorectal cancer

H. Nelson, H. Wieand, M. O’connell, 1996, Diseases of the colon and rectum.

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.

H. Wieand, J. Krook, M. O’connell, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

N. Petrelli, R. Beart, N. Wolmark, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.

S. Paik, S. Shak, J. Baker, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene Signatures in Stage II Colon Cancer: A Clinical Review

M. O’connell, S. Sharif, 2012, Current Colorectal Cancer Reports.

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.

H. Wieand, M. O’connell, D. Haller, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contents Vol. 10, 2010

P. Lescuyer, M. Macari, H. Friess, 2011, Pancreatology.

Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.

J. Glick, M. O’connell, E. Ezdinli, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer.

D. Sargent, P. Johnston, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locally recurrent colorectal cancer: IOERT and EBRT +/-5-FU and maximal resection.

S. Cha, H. Nelson, M. O’connell, 1997, Frontiers of radiation therapy and oncology.

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.

M. Oken, M. O’connell, E. Borden, 1992, The New England journal of medicine.

Clinical comparison of adriamycin and a combination of methyl‐CCNU and imidazole carboxamide in disseminated malignant melanoma

M. O’connell, D. Ahmann, J. Edmonson, 1976, Clinical pharmacology and therapeutics.

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

J. Earle, T. Habermann, S. Horning, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited.

M. O’connell, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I study of the combination N‐(phosphonacetyl)‐L‐aspartate (PALA, NSC‐224131) and L‐alanosine (NSC‐153353) in patients with advanced cancer

J. Kovach, M. O’connell, E. Creagan, 1983, Cancer.

An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy.

M. O’connell, D. Ahmann, J. Edmonson, 1977, The New England journal of medicine.

Lymphocytic lymphoma involving the middle ear.

M. O’connell, P. Banks, K. Olsen, 1980, Mayo Clinic proceedings.

A combined modality approach to the treatment of Hodgkin's disease. Preliminary results of a prospectively randomized clinical trial

M. O’connell, R. Byhardt, P. Wiernik, 1975, Cancer.

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

R J Reitemeier, P S Schein, J. Barkin, 1978, Cancer.

Second malignant lesions after therapy for Hodgkin's disease.

J. Earle, M. O’connell, P. Banks, 1984, Mayo Clinic proceedings.

Chemotherapy for colorectal carcinoma

M. O’connell, 1986, Ca.

Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma.

D. Sargent, J. Sloan, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.

M. O’connell, D. Ahmann, J. Edmonson, 1976, Cancer treatment reports.

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

M. Kahn, R. Fitzgibbons, J. Donohue, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.

L. Kvols, M. O’connell, J. Rubin, 1983, Cancer treatment reports.

Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome.

M. O’connell, J. Rubin, C. Moertel, 1984, Cancer treatment reports.

Transjugular liver biopsy: assessment of safety and efficacy of the Quick-Core biopsy needle

J. Crowe, J. Bruzzi, M. O’connell, 2002, Abdominal Imaging.

A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index.

J. Sloan, P. Novotny, C. Loprinzi, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146)

D. Sargent, J. Sloan, P. Novotny, 2011, Annals of Surgical Oncology.

A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study.

D. Kerr, S. Shak, D. Watson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.

Brian Bot, Greg Yothers, Qian Shi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.

Greg Yothers, Clifton D. Fuller, Mehee Choi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Innovative estimation of survival using log-normal survival modelling on ACCENT database

D. Sargent, P. Catalano, R. Gray, 2013, British Journal of Cancer.

Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.

David M. Thomas, R. Labianca, D. Sargent, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Percutaneous biopsy of periarterial soft tissue cuffs in the diagnosis of pancreatic carcinoma

E. Paulson, T. Jaffe, M. O’connell, 2003, Abdominal Imaging.

Status of adjuvant therapy for colorectal cancer.

N. Wolmark, J. Tepper, M. O’connell, 1989, Journal of the National Cancer Institute.

Transrectal ultrasound-guided biopsy of the prostate gland: value of 12 versus 6 cores

J. M. Fitzpatrick, J. Fitzpatrick, M. O’connell, 2003, Abdominal Imaging.

The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

T. Julian, N. Petrelli, S. Paik, 2008, Seminars in oncology.

Advanced colorectal adenocarcinoma: treatment with amonafide.

J. Kovach, M. O’connell, J. Rubin, 1994, Journal of the National Cancer Institute.

Model‐based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients

D. Sargent, S. Thibodeau, T. Smyrk, 2010, Cancer.

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

D. Sargent, M. Buyse, C. Boni, 2006, Annals of Surgical Oncology.

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

M. O’connell, N. Kay, M. Oken, 1990, Leukemia & lymphoma.

Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions

M. O’connell, Dulabh K. Monga, Michael J. O’Connell, 2006, Annals of Surgical Oncology.

Phase II trial of maytansine in patients with advanced colorectal carcinoma.

M. O’connell, J. Rubin, C. Moertel, 1978, Cancer treatment reports.

Prognostic web‐based models for stage II and III colon cancer

D. Sargent, A. Bardia, C. Loprinzi, 2011, Cancer.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

R. Goldberg, M. O’connell, C. Erlichman, 2001, The New England journal of medicine.

Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

N. Petrelli, N. Wolmark, M. O’connell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.

J. Kovach, M. O’connell, E. Creagan, 1980, Cancer treatment reports.

Erratum: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study (Annals of Hematology (1992) 65 (162-168))

J. Winter, M. O’connell, J. Bennett, 1993 .

Continuous Infusion Homoharringtonine (NSC 141633) in Refractory Acute Nonlymphocytic Leukemia: An ECOG Pilot Study

M. O’connell, J. Bennett, J. Stewart, 1988, American Journal of Clinical Oncology.

Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.

M. O’connell, J. Bennett, D. Adelstein, 1987, Seminars in oncology.

Nonspecific immune determinants in the patient with unresectable gastrointestinal carcinoma

M. O’connell, C. Moertel, R. E. Ritts, 1979, Cancer.

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

D. Sargent, B. Bot, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.

V. Sondak, M. Buyse, R. Carlson, 1997, Journal of the National Cancer Institute.

Assessing the Quality of Rectal Cancer Pathology Reports in National Surgical Adjuvant Breast and Bowel Project Protocol R-04/NRG Oncology

R. Beart, C. Ko, P. Ganz, 2020, Diseases of the colon and rectum.

Screening for colorectal cancer [1] (multiple letters)

D. Ransohoff, H. Anton-Culver, D. Lieberman, 2000 .

Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy

J. O'fallon, M. O’connell, E. Creagan, 2020 .

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.

S. Cha, D. Sargent, R. Goldberg, 2005, Clinical colorectal cancer.

Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.

M. O’connell, D. Haller, G. Yothers, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot

D. Sargent, J. Sloan, J. Laurie, 2002, Quality of Life Research.

Mediastinal adenopathy in granulocytic leukemia.

M. O’connell, G. Canellos, P. Wiernik, 1974, Archives of internal medicine.

Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer.

N. Petrelli, R. Beart, N. Wolmark, 2014 .

Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue.

S. Paik, J. Baker, D. Watson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Screening for colorectal cancer.

M. O’connell, K O'Brien, R O'Connell, 2000, The New England journal of medicine.

Radiation therapy quality control in a clinical trial of adjuvant postoperative treatment for rectal cancer.

J. Tepper, M. O’connell, L. Coia, 1995, International Journal of Radiation Oncology, Biology, Physics.

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

R. Labianca, D. Sargent, E. Van Cutsem, 2016, Journal of geriatric oncology.

Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.

M. O’connell, D. Ahmann, J. Edmonson, 1977, Cancer treatment reports.

Evaluation of a fixed alternating treatment in patients with advanced breast cancer.

J. O'fallon, J. Ingle, L. Kvols, 1978, Cancer clinical trials.

Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma.

M. O’connell, V. Go, C. Moertel, 1978, Annals of internal medicine.

Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma.

J. Earle, T. Habermann, J. Glick, 1994, Leukemia & lymphoma.

Conditional survival for patients with colon cancer: An analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) trials C-03 through C-06.

N. Wolmark, M. O’connell, J. Dignam, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of clinical therapeutic synergism between cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) in metastatic human colorectal carcinoma.

M. O’connell, E. Creagan, J. Rubin, 1980, Cancer treatment reports.

Final results of hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic (M-CRC) to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study.

D. Sargent, D. Nagorney, M. O’connell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attenuated High‐Dose Cytosine Arabinoside in the Treatment of the Elderly Patient with Acute Nonlymphocytic Leukemia: An Eastern Cooperative Oncology Group Pilot Study

M. O’connell, J. Bennett, S. Kahn, 1989, American journal of clinical oncology.

Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study.

J. Winter, M. O’connell, J. Wolter, 1990, Cancer Investigation.

Pancreatic cancer in the older patient.

M. O’connell, S. Alberts, S. Jacobson, 2001, Oncology.

Improved therapeutic ratio with protracted venous infusion (PVI) 5-fluorouracil (5FU) during postoperative external beam radiotherapy for high-risk rectal cancer

H. Wieand, J. Krook, M. O’connell, 1993 .

Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5‐fluorouracil and semustine

M. O’connell, R. Hahn, J. Rubin, 1988, Cancer.

Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?

D. Schaid, S. Thibodeau, J. Cunningham, 1992, Cancer.

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.

V. Sondak, M. Buyse, R. Carlson, 1996, Journal of the National Cancer Institute.

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

M. Buyse, J. Pignon, R. Carlson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of chlorozotocin (NSC 178248)

J. Ingle, J. Kovach, M. O’connell, 1979, Cancer.

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

D. Sargent, P. Catalano, R. Gray, 2011, Journal of Clinical Oncology.

Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum

N. Petrelli, N. Wolmark, M. O’connell, 2004 .

A VM 26‐based regimen for patients with previously untreated non‐Hodgkin lymphoma. Prolonged disease‐free survival in patients younger than 60 years of age: A phase II trial of the eastern cooperative oncology group

L. Gordon, M. O’connell, R. Hahn, 1993, Cancer.

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.

L. Gordon, J. Glick, M. O’connell, 1992, The New England journal of medicine.

Clinical Trial of Cisplatin and Intensive Course 5‐Fluorouracil for the Treatment of Advanced Colorectal Cancer

L. Kvols, M. O’connell, R. Hahn, 1986, American journal of clinical oncology.

Sam Wieand, PhD

D. Sargent, J. Costantino, N. Wolmark, 2006 .

Phase 1 trial and assay of rubidazone (NSC 164011) in patients with advanced solid tumors.

J. Kovach, M. O’connell, M. Ames, 1979, Cancer research.

Patterns of relapse in stages I, II and IIIA Hodgkin's disease: influence of initial therapy and implications for the future.

M. O’connell, P. Wiernik, J. Levi, 1977, International journal of radiation oncology, biology, physics.

Primary Lymphoma of the Testis

J. Earle, M. O’connell, P. Banks, 1983 .

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

N. Petrelli, S. Paik, N. Wolmark, 2013, Journal of the National Cancer Institute.

FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

N. Wolmark, M. O’connell, G. Yothers, 2008, Cancer investigation.

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

N. Petrelli, N. Wolmark, R. Goldberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

N. Petrelli, S. Paik, Chungyeul Kim, 2012, Clinical Cancer Research.

Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset

M. O’connell, 2007 .

Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas

D. Sargent, N. Foster, M. O’connell, 2008, Clinical Cancer Research.

Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04.

N. Petrelli, R. Beart, N. Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial and Assay of Rubidazone ( NSC 164011 ) in Patients with Advanced Solid Tumors

J. Kovach, M. O’connell, M. Ames, 2006 .

DNA ploidy is a stronger prognostic variable compared to microsatellite instability or 18q allelic loss in patients with stages II and III colon cancer

D. Sargent, S. Thibodeau, R. Goldberg, 2005 .

Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.

M. O’connell, D. Ahmann, J. Edmonson, 1976, Cancer treatment reports.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Computed tomography in search of cancer of unknown origin.

P. Sheedy, M. O’connell, P. Karsell, 1982, JAMA.